Quantum-Si Debuts New Headquarters in Branford, Connecticut
2023年6月7日 - 9:00PM
ビジネスワイヤ(英語)
World-class laboratory and office space
underpins the scaling of Quantum-Si’s operational and development
capabilities in support of its goal to revolutionize protein
sequencing.
Company continues rich 10 year history in
Connecticut with new facility through 2029
Quantum-Si- Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or
the “Company”), The Protein Sequencing Company™, today announced
the official debut of The Company’s new state-of-the-art, 29,420
square-foot headquarters in Branford, Connecticut. The new facility
extends The Company’s decade long history in Connecticut, and
includes a 7-year lease which will keep Quantum-Si in Branford at
least through 2029. The official ribbon cutting, hosted on June 6,
featured remarks from Quantum-Si Chief Executive Officer, Jeff
Hawkins; Quantum-Si founder Jonathan Rothberg, PhD.; and special
guests Governor Ned Lamont, US Senator Richard Blumenthal (D-CT),
and Alexandra Daum, the Commissioner of the Connecticut Department
of Economic and Community Development (DECD).
The new facility is located at 29 Business Park Drive in
Branford, Connecticut, and provides the resources necessary for
increased operational scale, development, and collaboration. This
milestone represents Quantum-Si's anticipated growth trajectory and
ability to support customers and partners using Platinum™, the
world’s first next-generation single-molecule protein sequencing
platform.
“The cities of Branford and Guilford, and State of Connecticut
have been incredible partners to Quantum-Si since our founding. Our
company’s roots are here, our relationships are here, and we want
to continue building a world-class company here.” said Quantum-Si's
Chief Executive Officer, Jeff Hawkins. “Our new headquarters
reflects the company’s ongoing commitment to job opportunities and
innovation alongside the local community. We believe New Haven
County is the perfect strategic location to attract world-class
scientific talent as we seek to grow our teams. We look forward to
leading the expansion of the life sciences industry in
Connecticut.”
“We have a truly transformative product on the market in
Platinum, the next-generation protein sequencer, a leadership bench
of highly experienced executives, and now we have the facilities to
scale alongside that growth” said Dr. Jonathan Rothberg, Founder
and Chairman of Quantum-Si. “Next-generation protein sequencing
will be critical for the discovery of a new wave of precision
therapies, and I am proud to see this work being done in the
community I call home."
“Quantum-Si’s clear commitment to cutting edge technology— and
to Connecticut— are truly thrilling. Connecticut has a long history
and tradition of being at the forefront of innovation and
Quantum-Si carries on that legacy with their next generation
protein sequencers that are advancing and accelerating our
understanding of medicine and human health.” Said Sen. Blumenthal.
“I am grateful and excited to have celebrated this milestone today
and look forward to Quantum-Si’s future endeavors in our
state.”
Platinum is the world’s first next-generation single-molecule
protein sequencing platform that uses proprietary recognizers to
identify proteins and amino acids using kinetic binding signatures.
Its elegant design and simple workflow enables broad-scale access
to proteomic data, for every scientist, everywhere, making it a
ground breaking platform for the future of proteomics research.
With its small benchtop design and low price-point, Platinum is
poised to accelerate breakthroughs across scientific disciplines,
from drug discovery to biotech, and help people live healthier and
longer lives.
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company™, is focused on
revolutionizing the growing field of proteomics. The Company's
suite of technologies is powered by a first-of-its-kind
semiconductor chip designed to enable next-generation
single-molecule protein sequencing and digitize proteomic research
in order to advance drug discovery and diagnostics beyond what has
been possible with DNA sequencing. Learn more at
quantum-si.com.
Forward Looking Statements
This press release includes "forward-looking statements" within
the meaning of the "safe harbor" provisions of the United States
Private Securities Litigation Reform Act of 1995. The actual
results of the Company may differ from its expectations, estimates,
and projections and, consequently, you should not rely on these
forward-looking statements as predictions of future events. Words
such as "expect," "estimate," "project," "budget," "forecast,"
"anticipate," "intend," "plan," "may," "will," "could," "should,"
"believes," "predicts," "potential," "continue," and similar
expressions (or the negative versions of such words or expressions)
are intended to identify such forward-looking statements. These
forward-looking statements include, without limitation, the
Company's expectations with respect to future performance and
development and commercialization of products and services. These
forward-looking statements involve significant risks and
uncertainties that could cause the actual results to differ
materially from those discussed in the forward-looking statements.
Most of these factors are outside the Company's control and are
difficult to predict. Factors that may cause such differences
include, but are not limited to: the impact of COVID-19 on the
Company's business; the inability to maintain the listing of the
Company's Class A common stock on The Nasdaq Stock Market; the
ability to recognize the anticipated benefits of the business
combination, which may be affected by, among other things,
competition and the ability of the Company to grow and manage
growth profitably and retain its key employees; the Company's
ongoing leadership transition; changes in applicable laws or
regulations; the ability of the Company to raise financing in the
future; the success, cost and timing of the Company's product
development and commercialization activities; the commercialization
and adoption of the Company’s existing products and the success of
any product the Company may offer in the future; the potential
attributes and benefits of the Company’s commercialized PlatinumTM
protein sequencing instrument and the Company’s other products once
commercialized; the Company's ability to obtain and maintain
regulatory approval for its products, and any related restrictions
and limitations of any approved product; the Company's ability to
identify, in-license or acquire additional technology; the
Company's ability to maintain its existing lease, license,
manufacture and supply agreements; the Company's ability to compete
with other companies currently marketing or engaged in the
development or commercialization of products and services that
serve customers engaged in proteomic analysis, many of which have
greater financial and marketing resources than the Company; the
size and growth potential of the markets for the Company's products
and services, and its ability to serve those markets once
commercialized, either alone or in partnership with others the
Company's estimates regarding future expenses, future revenue,
capital requirements and needs for additional financing; the
Company's financial performance; and other risks and uncertainties
described under "Risk Factors" in the Company’s Annual Report for
the fiscal year ended December 31, 2022, and in the Company's other
filings with the SEC. The Company cautions that the foregoing list
of factors is not exclusive. The Company cautions readers not to
place undue reliance upon any forward-looking statements, which
speak only as of the date made. The Company does not undertake or
accept any obligation or undertaking to release publicly any
updates or revisions to any forward-looking statements to reflect
any change in its expectations or any change in events, conditions,
or circumstances on which any such statement is based.
Source: Quantum-Si Incorporated
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230607005215/en/
Investor Contact Juan Avendano ir@quantum-si.com
Media Contact Michael Sullivan media@quantum-si.com
Quantum Si (NASDAQ:QSI)
過去 株価チャート
から 5 2024 まで 6 2024
Quantum Si (NASDAQ:QSI)
過去 株価チャート
から 6 2023 まで 6 2024